In MCF-7 breast cancer cells, treatment with EGCG at 30 μmol/L significantly inhibited cell proliferation and triggered apoptosis, potentially through modulation of the P53/Bcl-2 signaling pathway [139]. This evidence concerns the gene BCL2 and breast cancer.